Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation

IF 4.7 3区 生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Ahmed Rezk, Heba S. Said, Sherin M. Elfeky, Mohammed El-Mowafy, Ramadan Hassan
{"title":"Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation","authors":"Ahmed Rezk,&nbsp;Heba S. Said,&nbsp;Sherin M. Elfeky,&nbsp;Mohammed El-Mowafy,&nbsp;Ramadan Hassan","doi":"10.1007/s00253-026-13977-w","DOIUrl":null,"url":null,"abstract":"<p>The incidence of <i>Candida albicans</i> infections has risen markedly, particularly among immunocompromised individuals and cancer patients undergoing chemotherapy. Fluconazole is commonly used as a first-line treatment for <i>C. albicans</i> infections; however, increasing clinical resistance poses a significant therapeutic challenge. As a result, developing new strategies to enhance the management of <i>C. albicans</i> infections has become critical. This study aims to assess the prevalence of azole’s resistance among clinical <i>C. albicans</i> isolates in Egypt and to evaluate disulfiram/fluconazole combination against fluconazole resistant isolates. A total of 64 <i>C. albicans</i> clinical isolates were tested for fluconazole susceptibility using disc diffusion method and broth microdilution method (alone and in combination with disulfiram). The combination of fluconazole and disulfiram was further assessed using checkerboard method. The expression levels of resistance determinants were analyzed using RT-PCR. Molecular docking was used for further analysis. Sixteen isolates (25%) were resistant to fluconazole. Combination with subinhibitory concentration of disulfiram reduced the minimum inhibitory concentration (MIC) of fluconazole in resistant isolates (2–128 fold). Checkerboard assay revealed that fluconazole/disulfiram combination was mostly synergistic. In fluconazole-resistant isolates, <i>Cdr1</i> was overexpressed, whereas disulfiram (at subinhibitory concentration) has triggered its downregulation. Docking studies showed that disulfiram may compete with ATP for binding and may disrupt fluconazole's interaction with <i>Cdr1</i>. Additionally, disulfiram exhibited a potent anti-biofilm activity against the tested <i>C. albicans</i> isolates. Fluconazole/disulfiram combination appears to be a promising approach for overcoming fluconazole resistance in <i>C. albicans</i>. Further studies are needed to validate this finding and explore its clinical potential.</p><p>•<i> Fluconazole/disulfiram combination is a promising approach to overcome fluconazole resistance in C. albicans</i></p><p>• <i>Disulfiram triggered downregulation of Cdr1 expression in fluconazole-resistant C. albicans.</i></p><p>• <i>Disulfiram competes with ATP for Cdr1 binding, disrupting fluconazole-Cdr1 interaction.</i></p>","PeriodicalId":8342,"journal":{"name":"Applied Microbiology and Biotechnology","volume":"110 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00253-026-13977-w.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Microbiology and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s00253-026-13977-w","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The incidence of Candida albicans infections has risen markedly, particularly among immunocompromised individuals and cancer patients undergoing chemotherapy. Fluconazole is commonly used as a first-line treatment for C. albicans infections; however, increasing clinical resistance poses a significant therapeutic challenge. As a result, developing new strategies to enhance the management of C. albicans infections has become critical. This study aims to assess the prevalence of azole’s resistance among clinical C. albicans isolates in Egypt and to evaluate disulfiram/fluconazole combination against fluconazole resistant isolates. A total of 64 C. albicans clinical isolates were tested for fluconazole susceptibility using disc diffusion method and broth microdilution method (alone and in combination with disulfiram). The combination of fluconazole and disulfiram was further assessed using checkerboard method. The expression levels of resistance determinants were analyzed using RT-PCR. Molecular docking was used for further analysis. Sixteen isolates (25%) were resistant to fluconazole. Combination with subinhibitory concentration of disulfiram reduced the minimum inhibitory concentration (MIC) of fluconazole in resistant isolates (2–128 fold). Checkerboard assay revealed that fluconazole/disulfiram combination was mostly synergistic. In fluconazole-resistant isolates, Cdr1 was overexpressed, whereas disulfiram (at subinhibitory concentration) has triggered its downregulation. Docking studies showed that disulfiram may compete with ATP for binding and may disrupt fluconazole's interaction with Cdr1. Additionally, disulfiram exhibited a potent anti-biofilm activity against the tested C. albicans isolates. Fluconazole/disulfiram combination appears to be a promising approach for overcoming fluconazole resistance in C. albicans. Further studies are needed to validate this finding and explore its clinical potential.

• Fluconazole/disulfiram combination is a promising approach to overcome fluconazole resistance in C. albicans

• Disulfiram triggered downregulation of Cdr1 expression in fluconazole-resistant C. albicans.

• Disulfiram competes with ATP for Cdr1 binding, disrupting fluconazole-Cdr1 interaction.

双硫仑逆转白色念珠菌Cdr1介导的氟康唑耐药并干扰生物膜的形成。
白色念珠菌感染的发病率显著上升,特别是在免疫功能低下的个体和接受化疗的癌症患者中。氟康唑通常被用作治疗白色念珠菌感染的一线药物;然而,临床耐药性的增加给治疗带来了重大挑战。因此,制定新的战略以加强白色念珠菌感染的管理已变得至关重要。本研究旨在评估埃及临床白色念珠菌分离株对唑的耐药性,并评价双硫仑/氟康唑联合治疗对氟康唑耐药分离株的影响。采用圆盘扩散法和微量肉汤稀释法(单用和联用双硫仑)对64株临床分离的白色念珠菌进行氟康唑药敏试验。采用棋盘法进一步评价氟康唑与双硫仑的联用效果。采用RT-PCR分析耐药决定因子的表达水平。分子对接用于进一步分析。16株(25%)对氟康唑耐药。双硫仑联合亚抑制浓度可降低氟康唑耐药菌株的最低抑菌浓度(MIC)(2 ~ 128倍)。棋盘试验显示氟康唑/双硫仑联用主要是协同作用。在氟康唑耐药菌株中,Cdr1过表达,而双硫仑(亚抑制浓度)触发了其下调。对接研究表明,双硫仑可能与ATP竞争结合,并可能破坏氟康唑与Cdr1的相互作用。此外,双硫仑对白色念珠菌具有很强的抗生物膜活性。氟康唑/双硫仑联用似乎是克服白色念珠菌氟康唑耐药性的一种有希望的方法。需要进一步的研究来验证这一发现并探索其临床潜力。•氟康唑/双硫仑联用是克服白色念珠菌氟康唑耐药的一种很有前景的方法•双硫仑触发了氟康唑耐药白色念珠菌Cdr1表达的下调。•双硫仑与ATP竞争Cdr1结合,破坏氟康唑-Cdr1相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Applied Microbiology and Biotechnology
Applied Microbiology and Biotechnology 工程技术-生物工程与应用微生物
CiteScore
10.00
自引率
4.00%
发文量
535
审稿时长
2 months
期刊介绍: Applied Microbiology and Biotechnology focusses on prokaryotic or eukaryotic cells, relevant enzymes and proteins; applied genetics and molecular biotechnology; genomics and proteomics; applied microbial and cell physiology; environmental biotechnology; process and products and more. The journal welcomes full-length papers and mini-reviews of new and emerging products, processes and technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书